Epigenetic dysregulation is now a hallmark of several complex pathologies, including cancer, metabolic disorders, cardiovascular and neurological diseases.
Disease-specific epigenetic signatures such as DNA methylation, hydroxymethylation, and non-coding RNAs are now being utilized clinically for prognostics and diagnostics, while an expanding collection of genetically aberrant, abnormally expressed or chromatin-interacting epigenetic enzymes are positioned as promising targets for therapeutic intervention.